Stefano Molica

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 51

Top Topics

Psychometric Properties

Newly Diagnosed

Systematic Review

Chronic Lymphocytic Leukemia

Top Venues

American journal of hematology

Hematological oncology

Expert review of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Stefano Molica
Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints. Expert review of hematology (2024)
Stefano Molica, Francesca Romana Mauro
The new life of ibrutinib therapy in CLL: enhancing personalized approaches. Expert review of anticancer therapy (2024)
Stefano Molica, Francesca Romana Mauro
The new life of ibrutinib therapy in CLL: enhancing personalized approaches. Expert review of anticancer therapy 24 (9) (2024)
Stefano Molica, David John Allsup, Diana Giannarelli
Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American journal of hematology (2024)
Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Luca Laurenti, Massimo Massaia, Ramona Cassin, Marta Coscia, Caterina Patti, Elsa Pennese, Agostino Tafuri, Annalisa Chiarenza, Piero Galieni, Omar Perbellini, Carmine Selleri, Catello Califano, Felicetto Ferrara, Antonio Cuneo, Marco Murineddu, Gaetano Palumbo, Ilaria Scortechini, Alessandra Tedeschi, Livio Trentin, Marzia Varettoni, Fabrizio Pane, Anna Marina Liberati, Francesco Merli, Lucia Morello, Gerardo Musuraca, Monica Tani, Adalberto Ibatici, Giulia Regazzoni, Michele Di Candia, Maria Palma, Danilo Arienti, Stefano Molica
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Cancers 16 (6) (2024)
Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò, Carla Minoia, Roberta Murru, Paolo Sportoletti, Ferdinando Frigeri, Francesco Albano, Nicola Di Renzo, Alessandro Sanna, Luca Laurenti, Massimo Massaia, Ramona Cassin, Marta Coscia, Caterina Patti, Elsa Pennese, Agostino Tafuri, Annalisa Chiarenza, Piero Galieni, Omar Perbellini, Carmine Selleri, Catello Califano, Felicetto Ferrara, Antonio Cuneo, Marco Murineddu, Gaetano Palumbo, Ilaria Scortechini, Alessandra Tedeschi, Livio Trentin, Marzia Varettoni, Fabrizio Pane, Anna Marina Liberati, Francesco Merli, Lucia Morello, Gerardo Musuraca, Monica Tani, Adalberto Ibatici, Giulia Regazzoni, Michele Di Candia, Maria Palma, Danilo Arienti, Stefano Molica
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Cancers 16 (6) (2024)
Stefano Molica
Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints. Expert review of hematology (2024)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers 16 (6) (2024)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers 16 (6) (2024)
Stefano Molica, Francesca Romana Mauro
The new life of ibrutinib therapy in CLL: enhancing personalized approaches. Expert review of anticancer therapy (2024)
Stefano Molica
Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints. Expert review of hematology 17 (7) (2024)
Luca Laurenti, Lydia Scarfò, Anna Maria Frustaci, Alessandro Sanna, Emilia Iannella, Morena Caira, Paola Finsinger, Silvia Schifano, Benedetta Neri, Stefano Molica, Francesca Romana Mauro
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience. Hematological oncology (2023)
Stefano Molica, Constantine Tam, David John Allsup, Aaron Polliack
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers 15 (14) (2023)
Andrea Visentin, Francesca Romana Mauro, Lydia Scarfò, Massimo Gentile, Lucia Farina, Gianluigi Reda, Isacco Ferrarini, Giulia Proietti, Enrico Derenzini, Francesca Cibien, Candida Vitale, Alessandro Sanna, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Gian Matteo Rigolin, Paolo Sportoletti, Valentina Trimarco, Chiara Adele Cavarretta, Francesco Angotzi, Alessandro Cellini, Valeria Ruocco, Ivan Zatta, Luca Laurenti, Stefano Molica, Marta Coscia, Paolo Ghia, Robin Foà, Antonio Cuneo, Livio Trentin
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. American journal of hematology (2023)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population. American journal of hematology 99 (3) (2023)
Stefano Molica, Diana Giannarelli
Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis. Leukemia & lymphoma (2023)
Luca Laurenti, Lydia Scarfò, Anna Maria Frustaci, Alessandro Sanna, Emilia Iannella, Morena Caira, Paola Finsinger, Silvia Schifano, Benedetta Neri, Stefano Molica, Francesca Romana Mauro
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience. Hematological oncology (2023)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population. American journal of hematology 99 (3) (2023)
Paolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, Gianluca Gaidano, Elisa Albi, Francesca Romana Mauro, Francesco Angotzi, Daniele Vallisa, Fabrizio Pane, Antonio Cuneo, Francesco Albano, Giulia Zamprogna, Marta Coscia, Alessandro Gozzetti, Gianluigi Reda, Morena Caira, Paola Finsinger, Giuliana Gualberti, Emilia Iannella, Simona Malgieri, Stefano Molica
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. Hematological oncology (2023)
Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological oncology (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
David John Allsup, Stefano Molica
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report. Leukemia & lymphoma (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population. American journal of hematology (2023)
Stefano Molica, David Allsup
Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert review of anticancer therapy (2023)
Simone Oerlemans, Fabio Efficace, Charalampia Kyriakou, Ana Carolina Freitas, Omar Shamieh, Carien L Creutzberg, Jens Lehmann, Duska Petranovic, Eva Nagele, Anne Bredart, Dong Dong, Christian W Scholz, Giovanni Caocci, Stefano Molica, Laimonas Griskevicius, Aliki Xochelli, Jacobien M Kieffer, Joost A Agelink van Rentergem, Waleed Ismail Arljoub, Anja Mueller, Maria Gomes Da Silva, Filipa Alves da Costa, Sandra Malak, Kim Cocks, Lonneke V van de Poll-Franse, null null
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20). Cancer (2023)
Stefano Molica
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy. Expert review of hematology (2023)
Stefano Molica, Tait D Shanafelt, David John Allsup, Diana Giannarelli
Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population. American journal of hematology 99 (3) (2023)
Stefano Molica, Diana Giannarelli, Andrea Visentin, Gianluigi Reda, Paolo Sportoletti, Anna Maria Frustaci, Annalisa Chiarenza, Stefania Ciolli, Candida Vitale, Luca Laurenti, Lorenzo De Paoli, Roberta Murru, Massimo Gentile, Riccardo Moia, Gian Matteo Rigolin, Luciano Levato, Annamaria Giordano, Giovanni Del Poeta, Caterina Stelitano, Marina Deodato, Claudia Ielo, Alessandro Noto, Valerio Guarente, Marta Coscia, Alessandra Tedeschi, Gianluca Gaidano, Antonio Cuneo, Robin Foa', Livio Trentin, Francesca Romana Mauro
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. American journal of hematology 97 (5) (2022)
Simone Oerlemans, Fabio Efficace, Jacobien M Kieffer, Charalampia Kyriakou, Aliki Xochelli, Kerstin Levedahl, Duska Petranovic, Fabio Cardoso Borges, Anne Bredart, Omar Shamieh, Laimonas Gziskevicius, Jens Lehmann, Christian W Scholz, Giovanni Caocci, Stefano Molica, Kostas Stamatopoulos, Alkistis-Kyra Panteliadou, Maria Papaioannou, Waleed Alrjoob, Panagiotis Baliakas, Richard Rosenquist, Sandra Malak, Ana Miranda, Kim Cocks, Lonneke van de Poll-Franse, null null
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. British journal of haematology 197 (4) (2022)
Stefano Molica, Constantine Tam, Aaron Polliack
Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia. Hematological oncology 40 (3) (2022)
Stefano Molica, Diana Giannarelli
Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis. Leukemia (2022)
Stefano Molica, Diana Giannarelli, Emili Montserrat
mRNA COVID-19 vaccines in patients with CLL: A systematic review and meta-analysis. European journal of haematology (2021)
Stefano Molica, John F Seymour, Aaron Polliack
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematological oncology 39 (5) (2021)
Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, Gianluigi Reda, Livio Trentin, Paolo Sportoletti, Monia Marchetti, Daniela Pietrasanta, Roberto Marasca, Gianluca Gaidano, Marta Coscia, Caterina Stelitano, Donato Mannina, Nicola Di Renzo, Fiorella Ilariucci, Anna Marina Liberati, Lorella Orsucci, Francesca Re, Monica Tani, Gerardo Musuraca, Daniela Gottardi, Pier Luigi Luigi Zinzani, Alessandro Gozzetti, Annalia Molinari, Massimo Gentile, Annalisa Chiarenza, Luca Laurenti, Marzia Varettoni, Adalberto Ibatici, Roberta Murru, Valeria Ruocco, Ilaria Del Giudice, Maria Stefania De Propris, Irene Della Starza, Sara Raponi, Mauro Nanni, Paola Fazi, Antonino Neri, Anna Guarini, Gian Matteo Rigolin, Alfonso Piciocchi, Antonio Cuneo, Robin Foà
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers 14 (1) (2021)
Andrea Visentin, Francesca Romana Mauro, Francesca Cibien, Candida Vitale, Gianluigi Reda, Alberto Fresa, Stefania Ciolli, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Lydia Scarfò, Paolo Sportoletti, Stefano Pravato, Francesco Piazza, Marta Coscia, Luca Laurenti, Stefano Molica, Robin Foà, Antonio Cuneo, Livio Trentin
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. American journal of hematology 97 (3) (2021)
Gian Matteo Rigolin, Ilaria Del Giudice, Maria Antonella Bardi, Aurora Melandri, Rocio Edith García-Jacobo, Francesca Cura, Sara Raponi, Caterina Ilari, Luciana Cafforio, Alfonso Piciocchi, Valentina Arena, Gianluigi Reda, Francesco Albano, Stefano Molica, Paolo Sportoletti, Livio Trentin, Monia Marchetti, Mauro Nanni, Ilaria Del Giudice, Paola Mariglia, Marco Vignetti, Anna Rita Guarini, Francesca Romana Mauro, Robin Foà, Antonio Cuneo
COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY. Blood (2021)
Stefano Molica, Diana Giannarelli, Tycho Baumann, Emili Montserrat
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. European journal of haematology 104 (5) (2020)
Stefano Molica
Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia. International journal of hematologic oncology 9 (4) (2020)
Antonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N Allan, John M Pagel, Danielle M Brander, Brian T Hill, Allison M Winter, Nicole Lamanna, Constantine S Tam, Ryan Jacobs, Frederick Lansigan, Paul M Barr, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Alison R Sehgal, Stephen J Schuster, Nirav N Shah, Chaitra S Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, null null
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer medicine 9 (22) (2020)
Stefano Molica, Tycho Baumann, Diana Giannarelli
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis. European journal of haematology 106 (3) (2020)
Stefano Molica, Diana Giannarelli
Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis. Leukemia 35 (2) (2020)
Stefano Molica, Estella Matutes, Constantine Tam, Aaron Polliack
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematological oncology 38 (2) (2019)
Guido Carillio, Luigi Tucci, Stefano Molica
Classic Kaposi's sarcoma with an initial solitary colon lesion. Clinical case reports 7 (4) (2019)
Stefano Molica, Diana Giannarelli, Tait D Shanafelt
Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis. Leukemia & lymphoma 61 (4) (2019)
Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Tait D Shanafelt
Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. Annals of hematology 97 (10) (2018)
Guido Carillio, Stefano Molica
Unusual metastases of melanoma. Clinical case reports 6 (9) (2018)
Fortunato Morabito, Tait D Shanafelt, Massimo Gentile, Gianluigi Reda, Francesca Romana Mauro, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Annalisa Chiarenza, Giovanna Cutrona, Kari G Rabe, Sameer A Parikh, Giovanni Tripepi, Graziella D'Arrigo, Ernesto Vigna, Anna Grazia Recchia, Agostino Cortelezzi, Gianluca Gaidano, Francesco Di Raimondo, Franco Fais, Robin Foà, Antonino Neri, Manlio Ferrarini
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American journal of hematology 93 (9) (2018)
Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Massimo Gentile, Fortunato Morabito, Emili Montserrat
Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. American journal of hematology 92 (6) (2017)
Stefano Molica, Diana Giannarelli, Rosanna Mirabelli, Luciano Levato, Neil E Kay, Tait D Shanafelt
Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood 131 (3) (2017)
Massimo Gentile, Tait D Shanafelt, Francesca Romana Mauro, Luca Laurenti, Davide Rossi, Stefano Molica, Iolanda Vincelli, Giovanna Cutrona, Giuseppina Uccello, Sara Pepe, Ernesto Vigna, Giovanni Tripepi, Kari G Rabe, Sameer A Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. American journal of hematology 93 (2) (2017)